News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Says Alcon, Inc. (ACL)'s Eye Drug Jetrea Gets EU Approval



3/18/2013 7:57:46 AM

Novartis said its Alcon unit got a green light from the European Commission for Jetrea, a drug that treats an eye condition that can lead to blindness. Jetrea is the first eye drug to treat vitreomacular traction (VMT) associated with macular hole that can cause progressive sight-threatening symptoms and irreversible vision loss, Novartis said in a statement on Monday. Novartis has acquired the rights to sell Jetrea outside the United States from ThromboGenics NV. In October 2012, Jetrea was approved in the U.S. for the treatment of patients with symptomatic vitreomacular adhesion (VMA).

Read at Reuters
Read at News Release
Read at Market Watch


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES